SLC5A2 and diabetic cardiomyopathy: An ongoing clinical trial will assess the role of altered calcium handling in diabetic cardiomyopathy and heart failure and determine the effects of SGLT2-inhibitor therapy on cardiac calcium homeostasis (NCT04591639).